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IMPORTANCE
A significantly higher proportion of differentiated and multifunctional HSV-1 gB-specific effector memory CD8 ؉ T cells (T EM cells) (CD45RA low CCR7 low CD44 high CD62L low ) were found in healthy ASYMP individuals who are seropositive for HSV-1 but never had any recurrent herpetic disease, while there were frequent less-differentiated and monofunctional central memory CD8
؉ T cells (T CM cells) (CD45RA low CCR7 high CD44 low CD62L high ) in SYMP patients. Immunization with "ASYMP" CD8 ؉ T EM cell epitopes, but not with "SYMP" CD8
؉ T CM cell epitopes, induced a strong protective HSV-specific CD8 ؉ T cell response in HLA-A*02:01 transgenic mice. These findings are important for the development of a safe and effective T cell-based herpes vaccine.
O ver a billion individuals worldwide carry herpes simplex virus 1 (HSV-1), which causes a wide range of mild to life-threatening diseases (1) (2) (3) . Although the virus reactivates from latency and is shed multiple times each year in body fluids (i.e., tears, saliva, and nasal and vaginal secretions), most reactivations are subclinical due to an efficient immune-mediated containment of the infection and disease (4) (5) (6) (7) . Thus, most infected individuals are asymptomatic (ASYMP) and do not present any apparent recurrent herpetic disease (e.g., cold sores, genital, or ocular herpetic disease). However, a small proportion of individuals experience endless recurrences of herpetic disease, usually multiple times a year, often necessitating continuous antiviral therapy (i.e., with acyclovir and derivatives) (8, 9) . In those symptomatic (SYMP) individuals, HSV-1 frequently reactivates from latency, reinfects the eyes, and may trigger recurrent and severe corneal herpetic disease, a leading cause of infectious corneal blindness in the industrialized world (10) (11) (12) . In the United States, up to 450,000 individuals have a history of recurrent herpetic stromal keratitis (HSK), a T cell-mediated immunopathological lesion of the cornea (10) (11) (12) . Thus, a better understanding of the immune mechanisms that protect against HSV-1 infection and disease is highly desirable for the development of more efficacious vaccines and immunotherapies to reduce HSV-1-related diseases.
In animal models of herpes infection and disease, HSV-specific CD8 ϩ T cells play a critical role in aborting attempts of virus reactivation from latency and in clearing herpetic disease (3, 5, (13) (14) (15) (16) . However, herpetic corneal disease is also associated with HSV-specific CD8 ϩ T cell responses (17, 18) . While the HSV-1 glycoprotein B (gB) is a major target of CD8 ϩ T cells in seropositive ASYMP individuals (7, 19) , it produced only a transient protective immunity in vaccine clinical trials (12, 20, 21) . In B6 mice, an immunodominant CD8 ϩ T cell epitope, gB 498 -505 , achieved at least partial protection against herpes infection and disease (8, 12, 22, 23) . Considering the wealth of data addressing the phenotype and function of HSV-1 gB 498 -505 epitope-specific CD8 ϩ T cells in mice (4-6, 24, 25) , it is surprising how few reports exist characterizing the phenotype and function of human epitope-specific "protective" CD8 ϩ T cells from HSV-seropositive healthy ASYMP individuals, who appear to have acquired a "natural" protection (13, 26) . This information is necessary for the successful design of an effective T cell-based therapeutic vaccine strategy.
While memory CD8 ϩ T cell subpopulations are heterogeneous in terms of phenotype, function, and anatomical distribution, they can generally be divided into two major subsets: effector memory CD8 ϩ T cells (T EM cells) and central memory CD8 ϩ T cells (T CM cells) (26, 27) . The different characteristics of T CM and T EM cells suggest that they play different roles in recall responses and containment of herpes infection and disease (26, (28) (29) (30) . We hypothesize that ASYMP individuals develop more of the protective HSV-specific CD8 ϩ T EM cells, while SYMP patients develop more of the nonprotective (or maybe pathogenic) HSV-specific CD8 ϩ T CM cells (31, 32) . In this study, we found two distinct phenotypic and functional patterns of protective and nonprotective HSV-1 gB-specific CD8 ϩ T cells that are associated with ASYMP versus SYMP ocular herpes, respectively. A significantly higher proportion of differentiated HSV-1 gB-specific CD45RA low CCR7 low CD44 high CD62L low CD8 ϩ T EM cells were detected in ASYMP individuals. In contrast, a significantly higher proportion of less-differentiated HSV-1 gBspecific CD45RA low CCR7 high CD44 low CD62L high CD8 ϩ T CM cells were detected in SYMP patients. Moreover, the HLA-A*02: 01-restricted ASYMP HSV-1 gB epitopes, which specifically recalled polyfunctional CD8
ϩ T EM cell responses in HLA-A*02:01-positive ASYMP individuals, induced a CD8 ϩ T cell-dependent protective immunity against ocular herpes infection and disease in "humanized" HLA-A*02:01 transgenic (Tg) mice. In contrast, HLA-A*02:01-restricted SYMP gB epitopes, which tended to recall more monofunctional CD8
ϩ T CM cell responses in HLA-A*02:01-positive SYMP patients, were unable to protect HLA-A*02:01 Tg mice from ocular herpes.
Our findings delineate the quantitative and qualitative features of a protective HSV-specific CD8
ϩ T cell response that should be taken into consideration during herpes vaccine development.
MATERIALS AND METHODS
Human study population. During the last decade (i.e., January 2003 to August 2014), we have screened 693 individuals for HSV-1 and HSV-2 seropositivity (Table 1) . Four hundred eighty-eight individuals were white, 205 were nonwhite (African, Asian, Hispanic, and others), 355 were females, and 338 were males. Among these, a cohort of 261 immunocompetent individuals, with an age range of 18 to 65 (median, 32) and who were seropositive for HSV-1 and seronegative for HSV-2, were enrolled in the present study. All patients were negative for HIV and hepatitis B virus (HBV) and had no history of immunodeficiency. Six hundred seven patients were HSV-1, HSV-2, or HSV-1/HSV-2 seropositive, among whom 575 patients were healthy and ASYMP (individuals who, in the absence of therapy, have never had any recurrent herpes disease [ocular, genital, or elsewhere], based on their self-report and physician examination; even a single episode of any herpetic disease in his or her life span will exclude the individual from this group). The remaining 32 patients were defined as HSV-seropositive symptomatic patients and had frequent and severe recurrent genital, ocular, and/or oro-facial lesions, with two patients having had clinically well-documented repetitive herpes stromal keratitis (HSK) including one patient with ϳ20 episodes over 20 years that necessitated several corneal transplantations.
Signs of recurrent disease in SYMP patients were defined as herpetic lid lesions, herpetic conjunctivitis, dendritic or geographic keratitis, stromal keratitis, and iritis consistent with HSK, with one or more episodes per year for the past 2 years. However, at the time of blood collection, SYMP patients had no recurrent disease (other than corneal scarring) and had had no recurrences during the past 30 days. They had no ocular disease other than HSK, had no history of recurrent genital herpes, and were HSV-1 seropositive and HSV-2 seronegative. Because the spectrum of recurrent ocular herpetic disease is wide, our emphasis is mainly on the number of recurrent episodes and not on the severity of the recurrent disease. No attempt was made to assign specific T cell epitopes to specific severity of recurrent lesions. Patients were also excluded if they (i) had an active ocular (or elsewhere) herpetic lesion or one in the past 30 days, (ii) were seropositive for HSV-2, (iii) were pregnant or breastfeeding, or (iv) were on acyclovir or other related antiviral drugs or any immunosuppres- HLA typing. HLA-A2 subtyping was performed using a commercial sequence-specific primer (SSP) kit and following the manufacturer's instructions (SSPR1-A2; One Lambda, Canoga Park, CA). Briefly, genomic DNA extracted from peripheral blood mononuclear cells (PBMC) of HSV-seropositive SYMP and ASYMP individuals was analyzed using a Tecan DNA workstation from a 96-well plate with a 2-l volume per well, as we previously described (13) . The yield and purity of each DNA sample were tested using a UV spectrophotometer. The integrity of DNA samples was ascertained by electrophoresis on agarose gels. Each DNA sample was then subjected to multiple small-volume PCRs using primers specific to areas of the genome surrounding the single point mutations associated with each allele. Only primers that matched the specific sequence of a particular allele would amplify a product. The PCR products were subsequently electrophoresed on a 2.5% agarose gel with ethidium bromide, and the pattern of amplicon generation was analyzed using HLA Fusion software (One Lambda, Inc., Canoga Park, CA). In addition, the HLA-A2 status was confirmed by staining PBMC with anti-HLA-A2 monoclonal antibody (MAb) BB7.2 (BD Pharmingen, USA) at 4°C for 30 min. The cells were washed, acquired on a BD LSR II, and analyzed using FlowJo software version 9.7.5 (TreeStar).
PBMC isolation. Individuals (negative for HIV and HBV and with or without any HSV infection history) were recruited at the Gavin Herbert Eye Institute and the UCI Institute for Clinical and Translational Science (ICTS). Between 40 and 100 ml of blood was drawn into yellow-top Vacutainer tubes (Becton Dickinson, USA). The serum was isolated and stored at Ϫ80°C for detection of anti-HSV-1 and -HSV-2 antibodies, as we previously described (9) . PBMC were isolated by gradient centrifugation using leukocyte separation medium (Cellgro, USA). The cells were washed in phosphate-buffered saline (PBS) and resuspended in complete culture medium consisting of RPMI 1640 and 10% fetal bovine serum (FBS) (Bio-Products, Woodland, CA, USA) supplemented with 1ϫ penicillin-L-glutamine-streptomycin, 1ϫ sodium pyruvate, 1ϫ nonessential amino acids, and 50 M 2-mercaptoethanol (Life Technologies, Rockville, MD, USA). Freshly isolated PBMC were also cryopreserved in 90% fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO) in liquid nitrogen for future testing. For surface staining, MAbs against various cell markers were added to a total of 1 ϫ 10 6 PBMC in phosphate-buffered saline containing 1% FBS and 0.1% sodium azide (fluorescence-activated cell sorter [FACS] buffer) and left for 45 min at 4°C. After washing with FACS buffer, cells were permeabilized for 20 min on ice using the Cytofix/Cytoperm kit (BD Biosciences) and then washed twice with Perm/Wash buffer (BD Bioscience). Intracellular cytokine/intranuclear transcription factor-staining MAbs were then added to the cells and incubated for 45 min on ice in the dark. Cells were washed again with Perm/Wash and FACS buffer and fixed in PBS containing 2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO). For each sample, 200,000 total events were acquired on a BD LSRII. Antibody capture beads (BD Biosciences) were used as individual compensation tubes for each fluorophore in the experiment. To define positive and negative populations, we employed fluorescence-minus controls for each fluorophore used in this study, when initially developing staining protocols. In addition, we further optimized gating by examining known negative cell populations for background level expression. The gating strategy was similar to that used in our previous work (6) . Briefly, we gated on single cells, dump Ϫ cells, viable cells (Aqua Blue), lymphocytes, CD3 ϩ cells, and CD8 ϩ cells before finally gating human epitope-specific CD8 ϩ T cells using gB epitope-specific tetramers. The gB tetramers were prepared and provided by the NIH Tetramer Core Facility, Emory University, Atlanta, GA. Briefly, tetramers, were linked to streptavidin-PE (PJRS25; Prozyme) and adjusted to a concentration of 1 mg/ml. At a 1:1 ratio of streptavidin to phycobiliprotein, the addition of streptavidin to the biotinylated monomers was performed at room temperature. Data analysis was performed using FlowJo version 9.7.5 (TreeStar, Ashland, OR). Statistical analyses were done using GraphPad Prism version 5 (GraphPad, La Jolla, CA).
mRNA isolation and real-time reverse transcription-PCR (RT-PCR) analysis. Total RNA was isolated from fresh PBMC using the Direct-zol RNA MiniPrep kit (Zymo Research) and reverse transcribed with a highcapacity cDNA reverse transcription kit (Applied Biosystems) according to the manufacturer's instructions. Quantitative real-time PCR was carried out on a Rotor-Gene 3000 (Corbett Research) using the LightCycler 480 SYBR green 1 Master (Roche). The data were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) for transcription factor analysis. Relative mRNA expression levels were calculated using the following formula, and data are expressed as fold increase:
CD107 cytotoxicity assay. To detect gB-specific cytolytic CD8 ϩ T cells in PBMC, an intracellular CD107 a/b cytotoxicity assay was performed as described by Betts et al. (33) with a few modifications. Briefly, 1 ϫ 10 6 PBMC from patients were transferred into 96-well flat bottom plates and stimulated with immunodominant and subdominant gB peptide epitopes (10 g/ml in 200 l complete culture medium) in the presence of anti-CD107 a -FITC, CD107 b -FITC, and BD Golgi stop (10 g/ml) for 6 h at 37°C. Phytohemagglutinin (PHA) (10 g/ml) (Sigma) and no peptide were used as positive and negative controls, respectively. At the end of the incubation period, the cells were transferred to a 96-well round bottom plate and washed once with FACS buffer. Surface staining and intracellular staining were done as described above.
Virus production. HSV-1 (strain McKrae) was grown and titrated on RS (rabbit skin) cells. UV-inactivated HSV-1 was generated as we previously described (4). HSV inactivation was confirmed by the inability to produce plaques when tested on RS cells.
Immunization of HLA transgenic mice with SYMP and ASYMP epitope peptides, virus challenge and monitoring of ocular infection and disease. HLA-A*02:01 transgenic mice, previously described (34) (35) (36) , were kindly provided by Francois Lemonier (Pasteur Institute, Paris, France) and were bred at UCI. These mice represent the ϩ T cell epitopes mixed with CD4 ϩ T-helper PADRE epitope, as we described previously (34, 35) . All immunizations were carried out using 100 M each peptide epitope. After 2 weeks, mice were then challenged ocularly with 2 ϫ 10 5 PFU of HSV-1 (strain McKrae). Monitoring of ocular herpes infection and disease. Animals were examined for signs of ocular disease by slit lamp. Clinical assessments were made immediately before inoculation and on days 1, 4, 7, 10, 14, and 21 thereafter. The examination was performed by investigators blinded to the treatment regimen of the mice and scored according to a standard scale of 0 to 4, as previously described (3): 0, no disease; 1, 25% staining; 2, 50% staining; 3, 75% staining; and 4, 100% staining. Mice were segregated into two groups based on eye disease: ASYMP (without any ocular disease) and SYMP (with ocular disease). To quantify replication and clearance of HSV-1 from the eyes, mice were swabbed daily with moist type 1 calcium alginate swabs. Swabs were placed in 1.0 ml titration medium (media 199, 2% penicillin-streptomycin, 2% newborn calf serum) and frozen at Ϫ80°C until titrated on RS cell monolayers as described previously (3). Mice were also examined for survival in a window of 30 days after challenge, as we previously described (3).
Statistical analyses. Data for each assay were compared by analysis of variance (ANOVA) and Student's t test using GraphPad Prism 5 software (GraphPad, La Jolla, CA). Differences between the groups were identified by ANOVA and multiple-comparison procedures, as we previously described (37) . Data are expressed as the mean Ϯ standard deviation (SD). Results were considered statistically significant at a P value of Ͻ0.05.
RESULTS

HSV-seropositive symptomatic and asymptomatic individuals have different frequencies of CD8
؉ T cells specific to some HSV-1 gB epitopes. The characteristics of the symptomatic (SYMP) and asymptomatic (ASYMP) study populations used in the present study, with respect to gender, age, HLA-A*02:01 frequency distribution, HSV-1/HSV-2 seropositivity, and status of ocular herpetic disease are presented in Table 1 and detailed in Materials and Methods. Since HSV-1 is the main cause of ocular herpes, only individuals who were HSV-1 seropositive and HSV-2 seronegative were enrolled in the present study. The HSV-1-seropositive individuals were segregated into two groups: (i) 10 HLA-A*02:01-positive, HSV-1-infected ASYMP individuals who have never had any clinically detectable herpes disease and (ii) 10 HLA-A*02:01-positive HSV-1-infected SYMP individuals with a history of numerous episodes of well-documented recurrent clinical herpes diseases, such as herpetic lid lesions, herpetic conjunctivitis, dendritic or geographic keratitis, stromal keratitis, and iritis consistent with recurrent HSK, with 1 or more episodes per year for the past 2 years. One patient had over 20 severe recurrent episodes during the last 20 years that necessitated multiple corneal transplantations. Only SYMP patients who were not on acyclovir or other antiviral or anti-inflammatory drug treatments at the time of blood sample collections were enrolled.
To identify potential HLA-A*02:01-binding epitopes from HSV-1 gB, we previously searched the deduced HSV-1 (strain 17) gB amino acid sequence using the BIMAS, SYFPEITHI, and MAPPP predictive computational algorithms (Table 2) (13). Based on these analyses, we selected and synthesized 10 potential gB peptide epitopes with high predicted affinity to HLA-A*02:01, a haplotype that is represented in over 50% of the world's population, irrespective of gender and ethnicity (3, 5, 13) . Tetramers specific to each of the 10 HLA-A*02:01-restricted CD8 ϩ T cell epitopes were constructed.
We subsequently compared the frequencies of CD8 ϩ T cells specific to each gB epitope, using HLA-A*02:01-specific tetramers/anti-CD8 MAbs, in the peripheral blood of 10 HLA-A*02: 01-positive, HSV-1-seropositive ASYMP and 10 HLA-A*02:01-positive, HSV-1-seropositive SYMP individuals, as described above (Fig. 1) . The low frequencies of PBMC-derived HSV-specific CD8
ϩ T cells complicate a direct ex vivo detection with tetramers using a typical number of PBMC (ϳ10 6 cells), and a prior expansion of CD8 ϩ T cells by HSV-1 or peptide stimulation in an in vitro culture will hamper a reliable determination of the frequency, phenotype, and function of epitope-specific CD8 ϩ T cells. We therefore opted to measure the frequencies of gB epitope-specific CD8 ϩ T cells ex vivo using a large number of PBMC (ϳ10 ϫ 10 6 ) per tetramer/CD8 MAb panel. The representative dot plots shown in Fig. 1A indicate overall similar frequencies of CD8 ϩ T cells specific to two immunodominant (gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB [342] [343] [344] [345] [346] [347] [348] [349] [350] ) and two subdominant (gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB 561-569 ) epitopes detected in one ASYMP individual (top row) and one SYMP individual (bottom row). Figure 1B shows median frequencies detected in 10 SYMP and 10 ASYMP individuals. The highest and most significant frequencies of gB peptide tetramerpositive CD8 ϩ T cells that were consistently detected in both SYMP and ASYMP individuals were recorded for 3 out of 10 gB peptide epitopes: gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB [342] [343] [344] [345] [346] [347] [348] [349] [350] , and gB 561-569 (4.11% to 8.52%). The frequencies of CD8 ϩ T cells specific to the gB 183-191 epitope were similar in SYMP and ASYMP individuals (P ϭ 0.154), while frequencies of CD8 ϩ T cells recorded for gB 342-350 and gB 561-569 were slightly higher in ASYMP than in SYMP individuals (P ϭ 0.043 and P ϭ 0.041, respectively). Low frequencies of CD8 ϩ T cells against the gB 17-25 subdominant epitope were detected in both SYMP and ASYMP individuals. Despite repeated attempts, with and without in vitro expansions, the remaining six gB peptide/HLA-A*02:01 tetramers consistently detected nonsignificant frequencies of CD8 ϩ T cells in both SYMP and ASYMP individuals. We next determined whether there are any differences in the phenotype and function of gB epitope-specific effector and memory CD8 ϩ T cells between SYMP and ASYMP individuals.
Asymptomatic individuals have a higher frequency of HSV-1 gB epitope-specific CD8
؉ T EM cells, while symptomatic individuals have a higher frequency of CD8
؉ T CM cells. HSV-specific memory CD8
ϩ T cells are categorized into two major phenotypically distinct T EM and T CM subpopulations (3, 5, 13, 38) . We investigated whether SYMP and ASYMP individuals had different frequencies of HSV-specific CD8 ϩ T EM and T CM subpopulations. We gated on CD3 ϩ CD8 ϩ T cells that are specific to either the immunodominant (gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB [342] [343] [344] [345] [346] [347] [348] [349] [350] ) or the subdominant (gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB 561-569 ) gB epitopes, using the specific tetramers described above. As shown in Fig. 2A , B, C, and D, ASYMP individuals had significantly higher percentages of CD45RA low CCR7 low CD8 ϩ T EM cells specific to gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 342-350 immunodominant epitopes than SYMP individuals (P Ͻ 0.05). In contrast, we consistently detected significantly higher percentages of gB [183] [184] [185] [186] [187] [188] [189] [190] [191] Fig. 2G and H) (P ϭ 0.008). In contrast, significantly higher percentages of gB 561-569 epitope-specific CD44 high CD62L high CD8 ϩ T CM cells were detected in SYMP individuals than in ASYMP individuals (P ϭ 0.001). Similar profiles of memory CD8 ϩ T cell subpopulations were detected for the other subdominant gB17-25 epitope (data not shown).
The expression patterns of the T-bet and Eomes transcription factors, which are associated with T CM /T EM balance, were analyzed ex vivo in gB epitope-specific CD8 ϩ T cells from SYMP and ASYMP individuals at both the mRNA (using RT-PCR) and protein (using FACS) levels. As shown in Fig. 3A and D, a significantly higher proportion of CD8 ϩ T cells from ASYMP individuals than from SYMP individuals expressed Tbet and Eomes. In addition, a higher proportion of HSV-1 gB epitope-specific CD8 ϩ T EM cells from ASYMP individuals than from SYMP individuals were T-bet high ( Fig. 3B and C) and Eomes high ( Fig. 3E and F) (P ϭ 0.001). Altogether, the phenotypic properties of HSV-1 gB epitopespecific memory CD8
ϩ T cells revealed a clear dichotomy in memory CD8
ϩ T cell subpopulations in SYMP versus ASYMP
FIG 1 Similar frequencies of CD8
ϩ T cells specific to gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB [342] [343] [344] [345] [346] [347] [348] [349] [350] , and gB 561-569 epitopes detected in HLA-A*02:01-positive, HSV-seropositive SYMP and ASYMP individuals. PBMC (ϳ10 7 ) derived from ASYMP and SYMP individuals were analyzed ex vivo by FACS for the frequency of gB epitopespecific CD8
ϩ T cells using tetramer complexes representing each of the 10 potential gB epitopes shown in Table 2 individuals. By maintaining high frequencies of the "experienced" HSV-specific CD8 ϩ T EM cells, the ASYMP individuals should be better protected against infection and/or disease. The higher expression of T-bet and Eomes seen in ASYMP individuals may favor effector-to-memory CD8 ϩ T cell transition (EϾϾϾM) and the formation of a higher percentage of CD8 ϩ T EM cells (39) . Thus, the results suggest that at a subsequent pathogen encounter (e.g., following HSV-1 reactivation from latency), the ASYMP individuals, but not SYMP individuals, would mount much faster and stronger protective HSVspecific CD8 ϩ T EM cell responses, allowing a better clearance of herpes infection and disease.
HSV gB epitope-specific effector CD8 ؉ T cells from asymptomatic individuals are multifunctional compared to HSV gB epitope-specific CD8 ؉ T cells from symptomatic individuals. We next compared the function of HSV gB epitope-specific effec- 
tor CD8
ϩ T cells from SYMP versus ASYMP individuals. Because the frequency of the subdominant gB [17] [18] [19] [20] [21] [22] [23] [24] [25] epitope is so low, the functional studies were focused only on three epitopes: the immunodominant gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 342-350 epitopes and the subdominant gB 561-569 epitope.
We first compared the expression of granzyme B (GzmB), granzyme K (GzmK), and perforin (PFN) on gated gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB [342] [343] [344] [345] [346] [347] [348] [349] [350] , and gB 561-569 epitope-specific CD8 ϩ T cells from 10 SYMP and 10 ASYMP individuals (Fig. 4A) . We found high levels of GzmB, GzmK, and PFN expressed on gB 342-350 , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , and gB 561-569 epitope-specific CD8 ϩ T cells from ASYMP individuals compared to SYMP individuals, suggesting a positive correlation of strong HSV-specific CD8 ϩ T cell cytotoxic responses with protection from ocular herpetic disease (Fig. 4A) . A significantly higher frequency of GzmB ϩ CD8 ϩ T cells was detected in 10 ASYMP individuals than in 10 SYMP individuals (Fig. 4B and C) (P ϭ 0.001). A significant increase in the level of expression of GzmB, as determined by mean fluorescence intensity (MFI) (Fig.  4D and E) (P ϭ 0.001), and higher numbers of gB 561-569 epitopespecific GzmB ϩ CD8 ϩ T cells (Fig. 4F ) (P ϭ 0.007) were consistently detected in ASYMP individuals than in SYMP individuals. Similar trends were obtained for gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 342-350 epitopespecific GzmB ϩ CD8 ϩ T cells (data not shown). We then determined the level of expression of perforin by gB epitope-specific CD8 ϩ T cells and the numbers of PFN ϩ CD8 ϩ T cells from SYMP and ASYMP individuals. Significantly higher levels of PFN, determined by mean fluorescence intensity ( Fig. 4G and H) (P ϭ 0.001), and higher numbers of gB 561-569 epitope-specific CD8 ϩ T cells producing PFN, determined by tetramer staining (Fig. 4I ) (P ϭ 0.017) were detected in ASYMP individuals than in SYMP individuals. We observed similar trends of PFN expression on gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 342-350 epitope-specific PFN ϩ CD8 ϩ T cells from SYMP and ASYMP individuals (data not shown).
We next determined the ability of gB epitope-specific CD8 ϩ T cells from SYMP versus ASYMP individuals to produce IFN-␥ and degranulation marker CD107 a/b following in vitro stimulation. Freshly isolated CD8 ϩ T cells from SYMP and ASYMP individuals were stimulated in vitro for 6 h with individual immunodominant (gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 342-350 ) or subdominant (gB 561-569 ) epitope peptides, as described in Materials and Methods. The percentages and numbers of IFN-␥ ϩ CD8 ϩ T and CD107 a/bϩ CD8 ϩ T cells from SYMP and ASYMP individuals were compared by intracellular FACS staining. Significantly higher percentages (Fig. 4J and K) (P ϭ 0.001) and numbers ( Fig. 4L ) (P ϭ 0.007) of gB 561-569 epitope-specific CD8 ϩ T cells producing IFN-␥ were detected in ASYMP individuals than in SYMP individuals. A similar trend was obtained when CD8 ϩ T cells from SYMP and ASYMP individuals were stimulated by gB [183] [184] [185] [186] [187] [188] [189] [190] [191] or gB 342-350 peptide epitopes (data not shown). The level of CD107 a/b expression on the surface of CD8 ϩ T cells was used to determine epitope-specific cytotoxic function (33) . We observed significantly higher percentages ( SYMP and ASYMP individuals were stimulated by gB [183] [184] [185] [186] [187] [188] [189] [190] [191] or gB 342-350 peptide epitopes (data not shown).
We compared the polyfunctionality of gB 561-569 -specific CD8 ϩ T cells from ASYMP and SYMP individuals based on concurrent production of IFN-␥ and high expression levels of GzmB, GzmK, PFN, and CD107 a/b lytic granules. We found that 90% of ASYMP individuals had gB 561-569 -specific CD8 ϩ T cells with 3 to 5 functions, indicating their polyfunctional ability. In contrast, only 47% of SYMP individuals had gB 561-569 -specific CD8 ϩ T cells with 3 functions, while the majority had just one function, suggesting 
that CD8
ϩ T cells from SYMP patients tended to be monofunctional (Fig. 4P) (P ϭ 0.005) . Moreover, a significantly higher percentage of gB 561-569 -specific CD8 ϩ T cells from ASYMP individuals than from SYMP individuals upregulated Ki-67, indicative of increased proliferation (Fig. 4Q and R) (P ϭ 0.003). To determine the exhaustion status of HSV-specific effector CD8 ϩ T cells from SYMP versus ASYMP individuals, we analyzed the expression of PD-1, a marker of T cell exhaustion (40) . SYMP patients had higher expression of PD-1 than ASYMP individuals as shown by mean fluorescence intensity and numbers of gB 561-569 -specific PD1 ϩ CD8 ϩ T cells (Fig. 4S and T) (P ϭ 0.001), suggesting phenotypic exhaustion of HSV-specific CD8 ϩ T cells derived from SYMP patients.
Altogether, these results indicate the following. (i) HSV-gBspecific effector CD8 ϩ T cells from ASYMP individuals are multifunctional. In contrast, HSV-specific effector CD8 ϩ T cells from SYMP individuals are mostly monofunctional. (ii) High expression of PD-1 on HSV-1 gB-specific CD8 ϩ T cells from SYMP individuals also suggests more exposure to antigen than in ASYMP individuals, leading to dysfunction. (iii) The functional results suggest that, compared to SYMP individuals, ASYMP individuals are better prepared to mount protective cytotoxic and IFN-␥-producing CD8 ϩ T cells, two effector arms of immunity that protect against herpes.
Immunization with asymptomatic CD8 ؉ T EM epitopes, but not with symptomatic CD8
؉ T CM epitopes, elicits a strong CD8 ؉ T cell-dependent protective immunity against ocular herpes in the "humanized" HLA-A*02:01 transgenic mouse model of ocular herpes. Among the four gB epitopes identified in this study (gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB [342] [343] [344] [345] [346] [347] [348] [349] [350] , and gB 561-569 ), the most frequent, robust, and polyfunctional CD8 ϩ T EM cell responses detected in 10 ASYMP individuals were directed mainly against gB 342-350 and gB 561-569 epitopes, and these are hence designated ASYMP CD8 ϩ T EM epitopes (Fig. 2, 3 , and 4) (13). In contrast, frequent, but less robust, CD8
ϩ T CM cell responses detected in 10 SYMP individuals were directed mainly against gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB [183] [184] [185] [186] [187] [188] [189] [190] [191] epitopes, and these are hence designated SYMP CD8 ϩ T CM epitopes (Fig. 2, 3 , and 4) (13). We next set up a preclinical vaccine trial, using our established susceptible "humanized" HLA-A*02:01 transgenic mouse model (BALB/c genetic background) (13) , to evaluate whether immunization with ASYMP CD8 ϩ T EM epitopes confers protection against ocular herpes infection and disease.
Groups of susceptible HLA Tg mice (n ϭ 10 mice per group) were immunized subcutaneously twice, 21 days apart, with two ASYMP CD8 ϩ T EM cell epitope peptides (gB 342-350 and gB 561-569 ) (group 1) or with two SYMP T CM epitope peptides (gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB [183] [184] [185] [186] [187] [188] [189] [190] [191] ) (group 2). The CD8 ϩ T cell epitope peptides were delivered with the CD4 ϩ T helper PADRE epitope peptide mixed together and emulsified in CpG 1826 adjuvant, as we previously described (13) . As a negative control, mock-immunized mice received CpG 1826 adjuvant alone (group 3). Two weeks after the second and final immunization, animals from all groups received an ocular HSV-1 challenge (2 ϫ 10 5 PFU, McKrae strain) without scarification. The mice were then assessed for up to 30 days postchallenge for ocular herpes pathology, ocular viral titers, and survival.
As shown in Fig. 5A , on day 10 postinfection, the pathology clinical scores observed in the ASYMP group were significantly lower than those recorded in the SYMP group or the mock-immunized group (P ϭ 0.001 for all). Furthermore, significantly less virus was detected on day 7 postinfection (the peak of viral replication) in eye swabs of the ASYMP group than in the SYMP and mock-immunized groups (P ϭ 0.01) (Fig. 5B) . All animals in the ASYMP group survived lethal infection (100%), compared to only 10% survival in the SYMP group and 0% in the mock-immunized group (P Ͻ 0.005) (Fig. 5C) . Overall, there was a positive correlation between survival and the number of ASYMP CD8
ϩ T EM cells detected in the draining lymph nodes (DLN) of vaccinated mice (Fig. 5D ) (P Ͻ 0.001, r 2 ϭ 0.6753, 95% confidence interval [CI] ). To verify the implication of CD8 ϩ T cells in the observed protection induced following immunization with the ASYMP CD8 ϩ T EM cell epitopes, we performed an in vivo depletion of either CD4 ϩ or CD8 ϩ T cells in immunized mice before virus challenge, using specific MAbs. As shown in Fig. 5E , depletion of CD8 ϩ T cells, but not of CD4 ϩ T cells, significantly abrogated protection against death induced by immunization with the ASYMP CD8 ϩ T cell epitopes (P Ͻ 0.005), suggesting that, in this system, CD8 ϩ T cells, but not CD4 ϩ T cells, provided most of the protection against lethal ocular herpes.
Overall, these results indicate that immunization with ASYMP CD8 ϩ T EM cell epitope peptides, but not with SYMP T CM epitope peptides, decreased ocular herpes disease, decreased virus replication, and resulted in protection against lethal ocular herpes in susceptible HLA-A*02:01 Tg mice.
Frequent gB-specific CD8 ؉ T EM cells are detected in the corneas of HSV-1-infected "ASYMP" HLA-A*02:01 transgenic mouse. We next determined the frequency, phenotype, and function of CD8 ϩ T cells in the cornea of protected "ASYMP" and nonprotected "SYMP" HLA-A*02:01 Tg mice that were vaccinated and challenged with HSV-1, as described above. For simplicity only the extremes of ASYMP and SYMP mice were used for phenotypic and functional characterization of cornea-resident CD8 ϩ T cells. ASYMP mice had a clinical score of 1.0, while SYMP mice had a clinical score of 4 to 5.
We looked at the frequencies and numbers of gB 561-569 -specific CD8 ϩ T cells in corneas of ASYMP and SYMP mice. There were no significant differences in the frequencies and numbers of gB 561-569 -specific CD8 ϩ T cells in the two groups of mice ( Fig. 6A and B) (P ϭ 0.942). As shown in Fig. 6C and D, ASYMP mice had a significantly higher percentage and number of cornea-resident gB 561-569 -specific CD44 high CD62L low CD8 ϩ T cells with the T EM phenotype, compared to SYMP mice (65.2% Ϯ 4% versus 54.14% Ϯ 3%, P ϭ 0.0037). In contrast, significantly higher percentages and numbers of cornea-resident gB 561-569 -specific CD44 high CD62L high CD8 ϩ T CM cells were detected in SYMP mice than in ASYMP mice ( Fig. 6C and E) (P ϭ 0.001). Next, we determined the level of expression of GzmB, as determined by mean fluorescence intensity (MFI), in all four types of gB epitope-specific CD8 ϩ T cells. There was significantly higher expression of GzmB in ASYMP gB epitope-specific CD8 ϩ T cells than in SYMP gB epitope-specific CD8 ϩ T cells (Fig. 6F) . In addition, a higher percentage of gB epitope-specific CD8 ϩ T cells expressing GzmB was also detected in ASYMP corneas than in SYMP corneas, suggesting that there are more functional effector gB-specific CD8 ϩ T cells in ASYMP corneas (Fig. 6G) (P ϭ 0.001) .
Altogether, these results indicate that, similar to HLA-A*02: 01-positive ASYMP individuals, "ASYMP" HLA-A*02:01 Tg mice had frequent HSV-specific CD8 ϩ T EM cells retained in the cornea, poised to act as an early line of defense against future virus encounter. The results also support HLA-A*02:01 Tg mice as a useful animal model for investigating the underlying immune mechanisms by which CD8 ϩ T cells specific to HLArestricted HSV-1 epitopes mediate control of ocular herpes infection and disease.
DISCUSSION
Characterizing the phenotype and function of HSV-specific effector and memory CD8 ϩ T cells associated with ASYMP herpes infection is critical for the logical design of a T cell epitope-based herpes vaccine. The results presented in this report should yield new insights into the nature of protective HSV-specific CD8 ϩ T cells in humans and provide a framework for the rational design of vaccines that elicit long-term CD8 ϩ T cell protective immunity. We report that two major subpopulations of HSV-1 gB-specific
CD8
ϩ T cells, which possessed remarkably different phenotypes and functions, are maintained in SYMP versus ASYMP individuals. (i) ASYMP individuals had a significantly higher proportion of differentiated polyfunctional HSV-1 gB-specific CD8 ϩ T EM cells. In contrast, SYMP patients had significantly higher frequencies of less-differentiated monofunctional HSV-1 gB-specific CD8
ϩ T CM cells. (ii) Polyfunctional and robust T EM CD8 ϩ T cells from ASYMP individuals recognized mainly gB 342-350 and gB 561-562 T cell epitopes. In contrast, monofunctional and less robust T CM CD8 ϩ T cells in SYMP patients recognized mainly gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB [183] [184] [185] [186] [187] [188] [189] [190] [191] epitopes. (iii) Immunization with ASYMP gB 342-350 and gB 561-562 T EM epitopes, but not with SYMP gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB [183] [184] [185] [186] [187] [188] [189] [190] [191] T CM epitopes, protected susceptible HLA-A*02:01 transgenic mice from a highly pathogenic ocular herpes infection. To the best of our knowledge, this is the first report of phenotypic and func- ϩ T cell responses after challenge with HSV-1. Correlation was performed using the Pearson test with two-tailed P value analysis (r 2 ϭ 0.6753; P Ͻ 0.001) (r 2 ϭ correlation coefficient). (E) The protective immunity against ocular herpes induced by immunization with the ASYMP CD8 ϩ T EM cell human epitopes is abrogated following depletion of CD8 ϩ T cells but not of CD4 ϩ T cells. Following the second immunization, and before challenge with HSV-1, mice were injected intraperitoneally with six doses (i.e., 1 every other day) of 100 l of saline containing anti-CD4, anti-CD8, or isotype control. Flow cytometry analysis confirmed a decrease in spleen CD4 ϩ and CD8 ϩ T cells in treated mice to consistently less than 2% after MAb treatment. The P values compare protection achieved in MAb-treated versus untreated mice using ANOVA. Immunized, MAb-treated, and infected mice were examined for survival in a window of 30 days postchallenge. The indicated P values, calculated using one-way ANOVA, show statistically significant differences between protected "ASYMP" and nonprotected "SYMP" mice.
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Our understanding of the population size, the specificity, the phenotype, and the function of HSV-specific CD8 ϩ T cell populations derives mainly from mouse models of herpes infection (11, 23, 32, (41) (42) (43) . To gain insight into the nature of human HSVspecific CD8
ϩ T cell subpopulations, we used several human-focused immunological assays to characterize protective versus nonprotective HSV-1 gB-specific CD8
ϩ T cells at both effector and memory levels (13) . Our findings indicate that SYMP and ASYMP individuals have similar frequencies of HSV-1 gB epitope-specific CD8 ϩ T cells, suggesting that herpetic disease is not a consequence of a clonal deletion of specific repertoires of CD8 ϩ T cells in SYMP individuals. This result is in agreement with a recent study showing that once the clonal repertoire of HSVspecific CD8 ϩ T cells is established, it is kept constant for several years (44) . However, there were differences in T cells between SYMP and ASYMP individuals at the phenotypic and functional levels. The HSV-specific effector CD8 ϩ T cell subpopulations in HSV-1 seropositive SYMP and ASYMP individuals were categorized in two major phenotypes: phenotype 1 appeared predominantly in most SYMP individuals, was least effector-like, and had low expression of GzmB/perforin, low expression of Ki-67, and less production of IFN-␥ and CD107 a/b , while phenotype 2 appeared predominantly in most ASYMP individuals, was most effector-like, and had high expression of GzmB/perforin and Ki-67 and high production of IFN-␥ and CD107 a/b . Moreover, the majority of HSV-1 gB-specific memory CD8 ϩ T cells from ASYMP individuals and SYMP HLA-A*02:01 Tg mice were mainly of the T EM subpopulation, whileHSV-1 gB-specific CD8 ϩ T cells from SYMP individuals and SYMP HLA-A*02:01 Tg mice were mainly of the T CM subpopulation. Although the information gained from PBMC-derived CD8 ϩ T cells may not be completely reflective of tissue-resident CD8 ϩ T cells, because of the obvious ethical and practical considerations of obtaining tissue-resident CD8 ϩ T cells (i.e., from the human cornea and trigeminal ganglia [TG] , the sites of acute and latent infections, respectively), our investigations in humans were limited to human PBMC-derived CD8 ϩ T cells. Nevertheless, we were able to characterize T cells from corneas removed from HSV-1-infected SYMP and ASYMP "humanized" ϩ T cell epitopes (gB 17-25 and gB [183] [184] [185] [186] [187] [188] [189] [190] [191] ) and ASYMP gB-specific CD8 ϩ T epitopes (gB 342-350 and gB 561-569 ) (F) and frequencies of gB 561-569 epitope-specific GzmB ϩ CD8 ϩ T cells (G) from 5 ASYMP and 5 SYMP mice. The indicated P values, calculated using one-way ANOVA, show statistically significant differences between SYMP and ASYMP mice.
leaving behind only 5 to 10% of CD8 ϩ T cells destined to differentiate into a heterogeneous pool of memory CD8 ϩ T cells that can survive long-term in the absence of antigens (over 2 years in mice and over 50 years in humans) (39, 58, (61) (62) (63) . The CD8 ϩ T CM versus CD8 ϩ T EM cell lineage decision is influenced by many exogenous and endogenous factors, including the nature and strength of TCR signaling, cytokines (e.g., IL-2 and IL-15), and transcription factors (as we recently reviewed in reference 26). In the case of HSV-1, once primary infection has cleared, it is likely that certain human ASYMP epitopes (such as gB 342-350 and gB 561-569 ) may have the intrinsic ability to generate CD8 ϩ T EM cell subpopulations, which might have received signals during the primary response not to contract but instead to be maintained at high frequencies in peripheral tissues, as has been reported in other systems (64) (65) (66) (67) (68) . Thus, most ASYMP CD8 ϩ T EM cells (similar to T RM cells) may reside mainly in peripheral tissues, such as the cornea and TG, where they provide an efficient and quick response following HSV-1 infection/reactivation (39, 69-71)-a plausible explanation of decreased frequencies of recurrent disease in ASYMP individuals. In contrast, CD8
ϩ T CM cells specific to HSV-1 SYMP epitopes (such as gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB [183] [184] [185] [186] [187] [188] [189] [190] [191] ) might have received different signals that lead to increased expression of CD62L and CCR7 lymph node-directing molecules, making CD8
ϩ T CM cells destined to home to lymphoid organs instead of residing in peripheral tissues. Since SYMP CD8
ϩ T CM cells do not reside in peripheral tissues, they are unable to provide efficient immunosurveillance for HSV-1 infection/reactivation-a plausible explanation of increased frequencies of recurrent herpetic disease in SYMP individuals. Based on our present findings, we propose a mechanism built on a novel "symptomatic/asymptomatic concept," in which the immunopathology associated with corneal lesions is not a direct consequence of damage caused by the virus or by autoreactive or bystander T cells but rather results from the balance between "nonprotective" T CM cell responses specific to SYMP HSV-1 epitopes and protective T EM cell responses specific to ASYMP HSV-1 epitopes, as illustrated in Fig. 7 . Clearly, the polyfunctionality of HSV-specific ASYMP CD8
ϩ T EM cells is likely to be one of the important factors that accounts for the immunological control of herpes infection and disease. In contrast, monofunctional HSV-specific SYMP CD8
ϩ T CM cells may be involved in the appearance and/or exacerbation of immunopathological recurrent corneal disease. However, this does not exclude that other host or viral factors, acting either alone or in concert with cellular immune responses, can also play a role in determining the course of herpes infection and disease. Regardless of the mechanism, if ASYMP individuals develop protective CD8 ϩ T EM cells that recognize specific ASYMP epitopes while SYMP patients develop significantly larger frequencies of CD8 ϩ T CM cells that recognize nonoverlapping SYMP epitopes, it would be logical to exclude such SYMP epitopes from future herpes vaccines on the grounds that they may exacerbate rather than protect against recurrent herpetic disease. Lastly, we found a higher expression of PD-1 coinhibitory receptor on HSV-specific CD8 ϩ T cells from SYMP patients than on HSV-specific CD8 ϩ T cells from ASYMP individuals. This suggests that functional exhaustion of CD8 ϩ T cells may contribute to symptomatic herpes disease. We do not exclude that infection with a highly pathological strain of HSV-1 in SYMP individuals leads, by a yet-to-be-determined mechanism, to functionally compromised HSV-specific CD8 ϩ T cells. Differences in the immunological and pathological properties of HSV-2 strains from the United States and South Africa have been recently reported (72) . Although continuous production of antigens does not occur during latent HSV-1 infections, antigenic stimulation during sporadic reactivations of HSV-1 from latency may lead to T cell exhaustion. We are currently testing whether blockade of negative T cell costimulatory molecules, including PD-1, using specific MAb therapy in combination with vaccination will restore the function of exhausted HSV-specific CD8 ϩ T cells in latently infected HLA-A*02:01 Tg mice. This might enhance epitope-specific T EM cell responses in otherwise SYMP mice and protect against herpetic disease.
While developing an effective herpes vaccine is scientifically feasible, progress has been slow. Surprisingly, during the last 20 years only a single vaccine strategy, which consists of recombinant HSV glycoprotein D (gD) with or without gB, has been tested and retested in clinical trials (73) . This strategy, which obviously delivered both SYMP and ASYMP epitopes in one protein, failed to reach its primary endpoint of reducing herpes disease, in spite of its ability to induce strong HSV-specific neutralizing antibodies (73) . These failures emphasize the need for novel vaccine strategies that induce cell-mediated immunity (in addition to antibodymediated immunity) for better protection against herpes (74) . The present study supports this so-called "SYMP/ASYMP concept" by showing that immunization with ASYMP gB epitopes that are recognized mainly by CD8 ϩ T cells from "naturally" protected ASYMP individuals also protected HLA-A*02:01 Tg mice against ocular herpes infection and disease. In contrast, immunization with SYMP gB epitopes that are mainly recognized by CD8 ϩ T CM cells from SYMP patients did not protect. This novel approach is being extended in our laboratory to other HSV proteins, including tegument proteins, which are major targets of T cells (1) .
In this study, we choose HLA-A*02:01-positive individuals because the HLA-A*02:01 allele is present in over 50% of most populations worldwide, regardless of race and ethnicity (75) (76) (77) (78) . However, a question of practical importance is the translation of the current preclinical findings in HLA-A*02:01-positive individuals for the development of an epitope-based clinical vaccine for a genetically diverse and heterogeneous human population (11, 12, 21, 34, 79, 80) . A universal herpes vaccine should induce protective CD8
ϩ T cell responses in the context of many different HLA alleles. The high degree of HLA polymorphism, which might be a hindrance to epitope-based vaccines, can be dealt with by the inclusion of multiple HLA-restricted epitopes that are recognized in the context of diverse related HLA alleles and by designing peptide-based vaccines with high densities of ASYMP CD8 ϩ T cell epitopes. A combination of nine HLA supertypes has been defined to provide an almost perfect coverage (greater than 99%) of the entire repertoire of HLA molecules (81) . We previously demonstrated that immunization with multiple ASYMP epitopes produced polyclonal CD8 ϩ T cell lines (one T cell clone for each epitope) and broader effector and memory CD8 ϩ T cells than a single epitope (11, 82) . To further increase efficacy, a multiepitope-based peptide vaccine should include several ASYMP CD8 ϩ T cell epitopes from several different glycoproteins and tegument proteins (1), each chosen to represent the HLA supertypes known to provide recognition in a large proportion of the global population, regardless of race and ethnicity.
In summary, our study provides new insights about the phenotypes and the functions of HSV-specific CD8 ϩ T cell subpopulations that are associated with immunological control of herpes infection and disease in ASYMP individuals. It highlights the importance of CD8
ϩ T EM cells in antiviral defense against ocular HSV-1 infection and disease. Human ASYMP HSV-1 gB epitopes that specifically recalled polyfunctional CD8 ϩ T EM cell responses in HLA-A*02:01-positive, HSV-1-seropositive ASYMP individuals protected "humanized" HLA-A*02:01 Tg mice from ocular herpes infection and disease. In contrast, HLA-A*02:01-restricted SYMP epitopes derived from HSV-1 gB, which tended to recall monofunctional CD8
ϩ T CM cell responses in HLA-A*02:01-positive, HSV-seropositive SYMP patients, were unable to protect HLA-A*02:01 Tg mice from ocular herpes infection and disease. The findings demonstrate quantitative and qualitative features of an effective HSV-specific CD8
ϩ T cell response that should be taken into consideration in designing a T cell-based herpes vaccine.
